Nontuberculous Mycobacteria (NTM) Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Nontuberculous Mycobacteria Market Overview

The Nontuberculous mycobacteria market size in the US, the UK, and Japan was $8.59 billion in 2021 and is expected to achieve a CAGR of more than 2% during 2021-2031. The NTM market will grow as the diagnosed prevalent cases of nontuberculous mycobacteria (NTM) infections are expected to increase in the US, the UK, and Japan between 2021 and 2031.

The NTM market research report provides an analysis of the key dynamics of the NTM drugs market. The report also offers insights into the key industry drivers and challenges. It also covers deals and R&D strategies in detail to highlight potential business opportunities.

Nontuberculous Mycobacteria (NTM) Market Size To gain more information on the NTM market forecast, download a free report sample

NTM Market Drivers

Many pipeline agents are first-in-class therapies. This will drive the growth of the NTM market during the forecast period. Improving recognition and diagnosis of NTM in the healthcare community and the launch of improved and timely diagnostic tools that identify NTM species will further drive the growth of the market in focus in the coming years.

NTM Market Unmet Needs and Opportunities

There is a lack of late-stage pipeline products in development for antibiotics across the nontuberculous mycobacteria market. However, as the prevalence of NTM is increasing, drug companies are running campaigns to promote awareness and understanding of NTM among health care providers, patients, and the general public. This could lead to improved diagnosis and treatment rates, which will drive investment in the NTM market for R&D.

NTM Market Segmentation by Class of Drugs

The key classes of drugs in the NTM market are oral antibiotics, IV antibiotics, anti nausea, and nebulized antibiotics. In 2021, oral antibiotics had the largest market share in terms of value.

NTM Market Analysis, by Class of Drugs

 

NTM Market Analysis, by Class of Drugs

For more insights on classes of drugs in the NTM market, download a free report sample

NTM Market - Competitive Landscape

Some of the leading players in the NTM market are Insmed, RedHill Biopharma Ltd, Novartis AG, Paratek Pharmaceuticals Inc, Janssen, RevImmune, and Nobelpharma Co Ltd. Most of the companies had products in phase III of the development stage.

NTM Market Report Overview

Market Size (in 2021 in The US, The UK, and Japan) $8.59 billion
CAGR (2021 – 2031) >2%
Key Class of Drugs Oral Antibiotics, IV Antibiotics, Anti Nausea, and Nebulized Antibiotics
Leading Players Insmed, RedHill Biopharma Ltd, Novartis AG, Paratek Pharmaceuticals Inc, Janssen, RevImmune, and Nobelpharma Co Ltd

Scope

This report provides

  • Overview of NTM its pathogenicity, manifestations, and types of infection.
  • Epidemiology that looks into the diagnosed incident and prevalent cases of NTM by sex and by 3MM.
  • Overview of diagnostics and treatment, treatment profiles of combination therapy for different NTM strains.
  • Quotes from three key opinion leaders (KOLs) from the 3MM.
  • Key topics covered for NTM drugs in the 3MM include trends, pipeline and market analysis, opportunities, challenges, and unmet needs.
  • Pipeline assessment: emerging novel trends under development, and analysis of the most promising late-stage NTM pipeline drugs in clinical development.
  • Analysis of the key dynamics of the NTM drugs market. Insightful review of the key industry drivers and challenges.
  • Deals and R&D strategies covered in detail to highlight potential business opportunities.

Reasons to Buy

The report will help to understand:

  • What impact will late-stage pipeline agents have on the market? Which class of NTM drugs will have the highest peak sales, and why?
  • What country in the 3MM will experience the most growth, and why?
  • What are the current unmet needs and which pipeline drugs or strategies are positioned to counter these unmet needs? What are the opportunities for R&D in the NTM space?
  • How is the field of NTM therapies going to move forward?
  • What is the current and future outlook for NTM therapeutics according to KOLs?

Revimmune Inc
Novartis AG
Insmed Inc
Nobelpharma Co Ltd
Paratek Pharmaceuticals Inc
Revimmune LLC
RedHill Biopharma Ltd
RevImmune SAS
Insmed Ltd

Table of Contents

1 Executive Summary

1.1 Executive Summary

2 Disease Overview

2.1 Overview of Nontuberculous Mycobacteria

2.2 Nontuberculous Mycobacteria SWOT Analysis

3 Epidemiology

3.1 Diagnosed Prevalent Cases of NTM, Men and Women, 2021–31

3.2 Sources and Methodology

4 Current Treatment Options

4.1 NTM Diagnostic Paradigm

4.2 NTM Treatment Paradigm

4.3 NTM Current Treatment Options

4.4 Treatment Profile: Combination Therapy for Non-severe MAC Pulmonary Disease

4.5 Treatment Profile: Combination Therapy for Severe or Macrolide-Resistant Pulmonary MAC Disease

4.6 Treatment Profile: Combination Therapy for M. kansasii Disease

4.7 Treatment Profile: Combination Therapy for M. abscessus Disease

4.8 SWOT analysis: Antibiotic Combination Therapy

4.9 KOL analysis: Antibiotic Combination Therapy

5 Unmet Needs and Opportunities

5.1 Unmet Needs in NTM

6 Pipeline Assessment

6.1 NTM Pipeline Overview

6.2 Late-Stage Pipeline Agents

6.3 Product Profile: Arikayce

6.4 Product Profile: RHB-204

6.5 Product Profile: Clofazimine

6.6 Product Profile: Bedaquiline

6.7 Product Profile: Sargramostim

6.8 Product Profile: Omadacycline

6.9 Product Profile: CYT-107

6.10 KOL analysis: Pipeline Products

7 R&D Strategies

6.1 Trends in Deal-Making in NTM

6.2 Trends in Deal-Making in NTM

8 Market Outlook

8.1 NTM Market Forecast

8.2 Impact of COVID-19

8.3 Market Drivers and Barriers

9 Appendix

9.1 Bibliography

9.2 Primary Research: KOL Information

9.3 About the Authors

10 Contact Us

Frequently asked questions

Nontuberculous Mycobacteria (NTM) Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 standard reports
Currency USD
$9,995

Can be used by individual purchaser only

$29,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Nontuberculous Mycobacteria (NTM) Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
Venture Capital Investment Trends in Pharma - Q2 2026
$795 | July 2026
Pharmaceuticals
New
Merger and Acquisition Trends in Pharma - Q2 2026
$795 | July 2026
Pharmaceuticals
New
Emerging Market Outsourcing Report, Q2 2026
$2,950 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Nontuberculous Mycobacteria (NTM) Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 in real time.

  • Access a live Nontuberculous Mycobacteria (NTM) Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.